Expert Opinion on Orphan Drugs · 2015 · 72 citations · 71 references
Life SciencesPharmacologyPharmacotherapyClinical PharmacologyEnzymologyGeriatric PharmacotherapyEnzyme DeficienciesTherapeutic Enzymes6-Minute Walk TestComparative Clinical TrialsEnzyme Replacement TherapyEnzyme Substitution TherapySafety Of Enzyme Therapy
INTRODUCTION: Following a Phase III, randomized, double-blind, placebo (PBO)-controlled, multinational study in subjects with mucopolysaccharidosis IVA (MPS IVA), enzyme replacement therapy (ERT) of elosulfase alfa has been approved in several countries. The study was designed to evaluate safety and efficacy of elosulfase alfa in patients with MPS IVA aged 5 years and older. AREAS COVERED: Outcomes of clinical trials for MPS IVA have been described. Subjects received either 2.0 mg/kg/week, 2.0 mg/kg/every other week, or PBO, for 24 weeks. The primary endpoint was the change from baseline 6-min walk test (6MWT) distance compared to PBO. The 6MWT results improved in patients receiving 2 mg/kg weekly compared to PBO. The every other week regimen resulted in walk distances comparable to PBO. There was no change from baseline in the 3 Min Stair Climb Test in both treatment groups. Following completion of the initial study, patients, who continued to receive elosulfase alfa 2 mg/kg weekly (QW) for another 48 weeks (for a total of up to 72-week exposure), did not show additional improvement on 6MWT. EXPERT OPINION: We suggest that ERT is a therapeutic option for MPS IVA, providing a modest effect and the majority of the effects are seen in the soft tissues.
71
The metabolic and molecular bases of inherited disease
Ying-Tsong Chen · Medical Entomology and Zoology · 2001 · 6.9K citations
Shoichi Miyamoto, Noritoshi Nagaya, Toru Satoh et al. · American Journal of Respiratory and Critical Care Medicine · 2000 · 1.1K citations
Enzyme-Replacement Therapy in Mucopolysaccharidosis I
Emil Kakkis, Joseph Muenzer, George E. Tiller et al. · New England Journal of Medicine · 2001 · 675 citations · Full text
Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia
Michael P. Whyte, Cheryl R. Greenberg, Nada Salman et al. · New England Journal of Medicine · 2012 · 566 citations · Full text